NICE stays sour on As­traZeneca's Tagris­so

Months ago, British drug­mak­er As­traZeneca made its case for the use of Tagris­so as the first line of de­fense in cer­tain pa­tients with lung can­cer with an analy­sis that showed the drug helped pa­tients car­ry­ing the EGFR mu­ta­tion live longer ver­sus first-gen­er­a­tion ty­ro­sine ki­nase in­hibitors. But the UK’s cost-ef­fec­tive­ness watch­dog NICE is not con­vinced — on Wednes­day, the agency is­sued its fi­nal guid­ance re­fus­ing to en­dorse the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER